OXFORD, UK, May 29th, 2015.

PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.

This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.

Fintan Walton, CEO, PharmaVentures, commented: “Once again we are delighted to have delivered a successful and valuable outcome for our client and in the process secured hundreds of jobs.”

Nigel Borshell, VP, PharmaVentures, who was lead advisor added: “Our network of interested players in contract manufacturing and R&D plus our rigorous sale process has yet again delivered a positive outcome for our client”.

Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

– ends –

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. For the past 23 years, PharmaVentures has acted as advisor on over 700 deal related projects covering licensing, mergers, acquisitions, divestments and joint venture activities for companies world-wide.

Their unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more www.pharmaventures.com

Their services include:

  • M&A (divestments, mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now entering its 24th year, PharmaVentures is based in Oxford, UK, and employs 20 professionals and has associates in North America, Europe, Latin America and Asia-Pacific.


Dr Fintan Walton

Chief Executive

PharmaVentures Ltd

+44 1865 332700